Usted buscó: antikoagulanta (Esloveno - Inglés)

zamenjava parenteralnega antikoagulanta z zdravilom pradaxa
17 switching from parenteral anticoagulants treatment to pradaxa:

odmerek antikoagulanta bo morda treba prilagoditi;
the dose of your anticoagulant may need adjustment.

zdravilo teysuno je povečalo aktivnost kumarinskega antikoagulanta.
the activity of a coumarin-derivative anticoagulant was enhanced by teysuno.

prehod z antikoagulanta v injekciji na zdravilo pradaxa:
changing from anticoagulant treatment given by injection to treatment with pradaxa:

Če je treba se odmerek antikoagulanta prilagodi po potrebi.
if necessary, the oral anticoagulant dose should be adjusted as appropriate.

edoksabana in začetnega parenteralnega antikoagulanta ne smete dajati sočasno.
edoxaban and initial parenteral anticoagulant should not be administered simultaneously.

- antikoagulanta varfarin ali fenprokumon, ki se uporabljata za preprečevanje strjevanja krvi
- warfarin or phenprocoumon, anticoagulants used to prevent blood clots

- da bi prilagodili odmerek antikoagulanta in se izognili prekomerni hipokoagula bilnosti, je treba
- in order to adjust dosage of the anticoagulant and to avoid excessive hypocoagulability,

med zdravljenjem in kmalu po sočasni uporabi ciprofloksacina in peroralnega antikoagulanta je treba pogosteje določati vrednosti inr.
it is recommended that the inr should be monitored frequently during and shortly after co-administration of ciprofloxacin with an oral anti- coagulant agent.

poleg tega bo razširjena klinična uporaba varfarina kot antikoagulanta verjetno privedla do določitve sdv, če bo to potrebno.
furthermore, data available from the extensive clinical use of warfarin as an anticoagulant may confidently be expected to support the establishment of an adi, should this be considered necessary.

marcumar) vam bo zdravnik v primeru prekinitve zdravljenja z zdravilom xeloda morda moral prilagoditi odmerek antikoagulanta.
marcumar), stopping xeloda might require that your doctor adjusts your anticoagulant dose.

učinki zdravila revasc kot antikoagulanta so bili raziskani v štirih študijah, ki so zajele 1621 bolnikov, ki so prejemali zdravilo revasc.
the effectiveness of revasc as an anticoagulant has been studied in four studies involving 1,621 patients who received revasc.

ne sme se uporabljati pri bolnikih, ki jemljejo kateri koli drugi antikoagulant, razen v posebnih primerih, kot je denimo prehod z enega antikoagulanta na drugega.
it must not be used in patients taking any other anticoagulant medicine, except in specific situations such as when the anticoagulant medication is being switched.

priporočeni odmerek je 60 mg edoksabana enkrat na dan po začetni vsaj 5-dnevni uporabi parenteralnega antikoagulanta (glejte poglavje 5.1).
the recommended dose is 60 mg edoxaban once daily following initial use of parenteral anticoagulant for at least 5 days (see section 5.1).

3 o taki zamenjavi ni podatkov, zato ne priporočamo začetka dajanja zdravila pradaxa pred naslednjim običajnim odmerkom parenteralnega antikoagulanta (glejte poglavje 4. 5).
no data are available, therefore it is not recommended to start the administration of pradaxa before the next scheduled dose of the parenteral anticoagulant would have been due (see section 4.5).

bolnike, ki jemljejo antikoagulante kumarinskega tipa sočasno s kapecitabinom, moramo pazljivo spremljati in meriti njihove koagulacijske parametre (protrombinski čas ali inr) ter odmerek antikoagulanta ustrezno prilagajati.
patients taking coumarin-derivative anticoagulants concomitantly with capecitabine should be monitored regularly for alterations in their coagulation parameters (pt or inr) and the anticoagulant dose adjusted accordingly.

učinkovitost zdravila iscover kot antikoagulanta so preučevali v okviru študije (caprie), ki je vključevala približno 19. 000 bolnikov z aterotrombozo, pri čemer so zdravilo iscover primerjali z aspirinom.
the effectiveness of iscover as an anticoagulant was examined in a study (caprie) of around 19,000 patients with atherothrombosis, where iscover was compared with aspirin.

bolnikom, ki prejemajo peroralni kumarinski antikoagulant, je treba skrbno spremljati antikoagulantni odziv (mednarodno normalizirano razmerje za protrombinski čas (inr) ali protrombinski čas (pt)) ter ustrezno prilagajati odmerek antikoagulanta (glejte poglavje 4.5).
patients receiving oral coumarin-derivative anticoagulant therapy must have their anticoagulant response (international normalized ratio for prothrombin time [inr] or prothrombin time [pt]) monitored closely and the anticoagulant dose adjusted accordingly (see section 4.5).